BamSEC and AlphaSense Join Forces
Learn More

Ocugen, Inc. – Material Contracts

NASDAQ: OCGN    
Share price (8/6/26): $1.24    
Market cap (8/6/26): $420 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 5 pages Letter Agreement Regarding Equity Awards This Letter Agreement (This “Agreement”) Is Entered Into as of January 20, 2026 (The “Effective Date”), by and Between Ocugen, Inc., a Delaware Corporation (The “Company”), and Shankar Musunuri (The “Participant”)
12/34/56
EX-10.1
from 8-K 11 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.2
from 10-Q 40 pages Material contract
12/34/56
EX-10.1
from 10-Q 42 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”
12/34/56
EX-10.2
from 8-K 14 pages Placement Agency Agreement August 8, 2025
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Third Amendment to the Exclusive License Agreement
12/34/56
EX-10.4
from 8-K 5 pages Lock-Up Agreement [●], 2025
12/34/56
EX-10.3
from 8-K 19 pages Support Agreement
12/34/56
EX-10.2
from 8-K 19 pages Support Agreement
12/34/56
EX-10.1
from 8-K 177 pages Agreement and Plan of Merger by and Among Carisma Therapeutics Inc., Azalea Merger Sub, Inc., Orthocellix, Inc. and Ocugen, Inc. Dated as of June 22, 2025
12/34/56
EX-10.38
from 10-K 12 pages Material contract
12/34/56
EX-10.1
from 8-K/A 15 pages Subscription Agreement
12/34/56
EX-10.1
from 10-Q 11 pages Executive Employment Agreement
12/34/56
EX-10.25
from 10-K 2 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and the Registrant Customarily and Actually Treats as Private and Confidential. Second Amendment to the Exclusive License Agreement Between the Washington University| and Ocugen, Inc
12/34/56
EX-10.22
from 10-K 2 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and the Registrant Customarily and Actually Treats as Private and Confidential. 3rd Amendment to Co-Development and Commercialization Agreement
12/34/56
EX-10.1
from 8-K 8 pages Ocugen, Inc. 2019 Equity Incentive Plan Performance Restricted Stock Unit Grant Notice and Performance Restricted Stock Unit Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Executive Employment Agreement
12/34/56
EX-10.31
from 10-K 2 pages Amendment #1 to Amended & Restated Executive Employment Agreement
12/34/56
EX-10.30
from 10-K 8 pages Amended & Restated Executive Employment Agreement
12/34/56